

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

OVERSEAS REGULATORY ANNOUNCEMENT

This overseas regulatory announcement is issued pursuant to Rule 13.10B of the Listing Rules.

Reference is made to the announcements (the “**Announcements**”) of Luye Pharma Group Ltd. (the “**Company**”) dated 23 October 2024, 28 October 2024, 30 October 2024, 13 December 2024, 1 August 2025, 14 August 2025, 20 August 2025 and 9 September 2025 in relation to, among other things, the issue by the Company of US\$100,000,000 5.85 per cent. convertible bonds due 2025 (the “**Tranche A Bonds**”) and US\$50,000,000 5.85 per cent. convertible bonds due 2025 (the “**Tranche B Bonds**”), and the partial conversions of the Tranche A Bonds. Unless the context requires otherwise, capitalised terms used herein have the same meanings as those defined in the Announcements.

Please refer to the attached announcement dated 10 September 2025 in relation to the conversion of the Tranche A Bonds in the principal amount of US\$15,000,000 and the conversion of the Tranche B Bonds in the principal amount of US\$10,000,000, each at the conversion price of HK\$3.672 per Share, which was published on the website of Singapore Exchange Securities Trading Limited on 10 September 2025.

The posting of the attached announcement with this announcement on the website of Hong Kong Exchanges and Clearing Limited and on the Company’s website is only for the purpose of facilitating equal dissemination of information to investors in Hong Kong and compliance with Rule 13.10B of the Listing Rules, and not for any other purposes.

The attached announcement must not be regarded as an inducement to subscribe for or purchase any securities of the Company, and no such inducement is intended.

By order of the Board
LUYE PHARMA GROUP LTD.

Liu Dian Bo

Chairman

Hong Kong, 10 September 2025

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.

LUYE PHARMA GROUP LTD.
(Incorporated in Bermuda with limited liability)

CONVERSION OF CONVERTIBLE BONDS

References are made to the announcements (the “**Announcements**”) of Luye Pharma Group Ltd. (the “**Company**”) dated 23 October 2024, 28 October 2024, 30 October 2024 and 13 December 2024 which were published on the website of The Stock Exchange of Hong Kong Limited and dated 1 August 2025, 14 August 2025, 20 August 2025 and 9 September 2025 which were published on the website of the SGX-ST in relation to, among other things, the issue by the Company of US\$100,000,000 5.85 per cent. convertible bonds due 2025 (the “**Tranche A Bonds**”) and US\$50,000,000 5.85 per cent. convertible bonds due 2025 (the “**Tranche B Bonds**”, together with the Tranche A Bonds, the “**Bonds**”), and the partial conversions of the Tranche A Bonds. Unless the context requires otherwise, capitalised terms used herein have the same meanings as those defined in the Announcements.

On 9 September 2025, the Company received conversion notices from a holder of the Bonds (the “**Bondholder**”) in relation to the exercise of the conversion rights attached to (i) the Tranche A Bonds, to convert the Tranche A Bonds in the principal amount of US\$15,000,000 (the “**Tranche A Bonds Conversion**”) and (ii) the Tranche B Bonds, to convert the Tranche B Bonds in the principal amount of US\$10,000,000 (the “**Tranche B Bonds Conversion**”, together with the Tranche A Bonds Conversion, the “**Conversion**”), each at the conversion price of HK\$3.672 per Share. Accordingly, a total of 52,919,388 Shares (being the sum of 31,751,633 Shares in respect of the Tranche A Bonds Conversion and 21,167,755 Shares in respect of the Tranche B Bonds Conversion), representing approximately 1.343 per cent. of the issued share capital of the Company immediately before the Conversion and approximately 1.325 per cent. of the issued share capital of the Company immediately after the Conversion (the “**Conversion Shares**”), were allotted to the Bondholder on 10 September 2025 pursuant to the terms and conditions of the Tranche A Bonds and the Tranche B Bonds. The Conversion Shares rank *pari passu* and carry the same rights and privileges in all respects among themselves and with all other existing Shares in issue.

Immediately before the Conversion, there were in total an aggregate number of 3,941,596,565 Shares and the outstanding principal amounts of the Tranche A Bonds and the Tranche B Bonds were US\$15,000,000 and US\$50,000,000, respectively. Immediately after the Conversion, (i) there are in total an aggregate number of 3,994,515,953 Shares, (ii) no Tranche A Bonds are outstanding, and (iii) the outstanding principal amount of the Tranche B Bonds is US\$40,000,000. Accordingly, the Tranche A Bonds will be delisted from the SGX-ST.

By order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

10 September 2025